Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donors
The use of PBPC mobilized by filgrastim (G-CSF) as a source of hematopoietic cells for patients undergoing allogeneic transplantation may provide advantages for donors and recipients.
There are increasing data regarding the short-term effects of G-CSF in adult donors. Recently, an agreement was reached on donor safety by a group of investigators actively involved in the field of allogeneic stem cell transplantation. 1 Data about the long-term safety of G-CSF are currently lacking. Most of the data available are from patients with congenital neutropenia or aplastic anemia.
However, there is very limited experience with pediatric donors.
2-4 Herein we report the preliminary data regarding short-term safety in pediatric donors undergoing G-CSF mobilization and PBPC collection by large-volume leukapheresis (LVL). Donor characteristics are given in Table  1 . Informed consent was obtained from patients, donors or their parents as appropiate. They were mobilized by G-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA). G-CSF was administered subcutaneously once a day at a dose of 10 g/kg/day for 4-5 days. No significant side-effects were observed except for moderate bone pain in four cases. Venous access was obtained by venipuncture of both arms in one donor and in the others, a central venous catheter was necessary to achieve adequate venous flow. Femoral access was chosen to place central venous catheters in order to minimize the insertion-related risk, with adequate measures to prevent or manage potential complications. PBPC collections were performed on day ϩ5 after G-CSF mobilization by a Cobe Spectra blood cell separator (COBE, Denver, CO, USA) using acid-citrate-dextrose-adenine (ACD-A) as anticoagulant. Details of large-volume leukapheresis have been previously reported. 5 A total of six leukaphereses were performed in five donors. Two aphereses were necessary in a donor weighing 10 kg because his recipient weighed 43 kg. Apheresis characteristics are shown in Table 2 . The CD34 ϩ cell target dose for trans- Table 2 .
In general, PBPC donors should meet eligibility criteria for platelet donation. Children are usually excluded, but can be included as PBPC donors where necessary. Certainly, the use of minors as PBPC donors represents an ethical dilemma, 6 which from our point of view is no greater than that posed by bone marrow donation for a relative. Technical problems, 5 possible psychological impact of leukapheresis and ethical issues, have made reduction of the number of procedures desirable. Large volume leukapheresis, defined as processing greater than three volumes of blood in a single session, 5 has been easily performed, well tolerated and maximizes PBPC yield for allogeneic transplantation in adults. 7 We successfully harvested sufficient progenitor cells from pediatric donors for allogeneic transplantation by LVL without major complications. G-CSF administration at a dose of 10 g/kg/day mobilized enough progenitor cells 
Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect
Abraham et al 1 report their experience with shortening the duration of post-transplant immunosuppression by rapid tapering of cyclosporin (CsA) between 30 and 60 days in adult patients at high risk of relapse of AML and with no evidence of acute GVHD. They concluded that an early taper of CsA can be used with reasonable safety in a high risk population undergoing allogeneic BMT. Our unit had adopted a similar policy in children for acute leukaemia. Between January 1993 and October 1997, 24 children underwent BMT for acute leukaemia from fully matched sibling donors and received CsA and MTX as GVHD prophylaxis. Age at BMT was 2.4-11.7 years (median 7.3); 14 were males and 10 females. The main groups were ALL (conditioned with TBI 1320cGy in 8 fractions over 4 days/CY, 120 mg/kg); 12 patients were in CR 2 , and five high risk patients in CR 1 . Seven patients with AML were conditioned with BU 600 mg/m 2 /CY 120 mg/kg; six were in CR 1 and one was in early relapse. GVHD prophylaxis consisted of MTX, 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, 6 and 11. All were treated according to a common CsA regimen, with 3 mg/kg i.v. from day −1 followed by oral treatment when tolerated. In the absence of GVHD by day +30, a rapid taper of CsA was commenced, with the aim of ceasing CsA by day +100. Treatment with CsA was continued and systemic steroids added for treatment of acute GVHD. There was one early transplant-related mortality. Of the remaining 23 patients, 12 had no evidence of acute GVHD and underwent CsA taper followed by early discontinuation at a median of 92 days post BMT (range 77-112 days). Eleven patients received steroids and continued CsA for GVHD (n = 9) or suspected GVHD (n = 2). However, in this group CsA was still discontinued by a median of day +226 (167-380). Of those who developed acute GVHD, eight had grades I and II, one had grade III and none developed grade IV. The two patients who developed chronic GVHD ceased CsA on days +256 and +380. No patient developed chronic GVHD after commencing the rapid taper of CsA.
Of the 24 patients, 20 are alive and disease free, one is alive and in relapse, three died: one was the early transplant-related death mentioned above; there was a fatal second malignancy; one of the patients who had chronic skin GVHD had also developed RSV pneumonitis on day 0 of her transplant, and had multiple organ problems. This patient continued to have progressive restrictive respiratory symptoms after all signs of GVHD had abated and died of respiratory failure. At no time had GVHD been considered as part of her lung pathology. Duration of follow-up for the 21 survivors ranged from 0.46 to 5.03 years (median 2.15).
Relapse after allogeneic HLA-identical BMT for acute leukaemia is the major cause of therapeutic failure of this procedure. Graft-versus-leukaemia effect may help prevent the recurrence of haematological malignancy following allogeneic BMT.
1-3 Such an effect may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of CsA. 1 We do not know the required duration of immunosuppression for prevention of GVHD. A common approach to withdrawal of CsA is gradual dosage taper over 6 months to 1 year. Omission of any GVHD prophylaxis is associated with a high rate of GVHD, even in children. 4 Individualised prophylaxis against GVHD
